Characterizing drug resistance using geometric ensembles from HIV protease dynamics
Olivier Sheik AmamuddyiD, Nigel T. BishopiD, Özlem Taştan BishopiD
Abstract
The use of antiretrovirals (ARVs) has drastically improved the life quality and expectancy of HIV patients since their introduction in health care. Several millions are still afflicted worldwide by HIV and ARV resistance is a constant concern for both healthcare practitioners and patients, as while treatment options are finite, the virus constantly adapts and selects for resistant viral strains under the pressure of drug treatment. The HIV protease is a crucial enzyme that processes viral polyproteins into their functional form, and has been a game changing drug target since the first application. Due to similarities in protease inhibitor designs, drug cross-resistance is not uncommon across ARVs of the same class. It is known that resistance against protease inhibitors is associated with a wider active site, but results from our large scale molecular dynamics analysis further show, for the first time, that there are regions of local expansions and compactions associated with high levels of resistance conserved across eight different protease inhibitors visible in their complexed form in closed receptor conformations. The method developed here is novel, supplementary to the methods of nonsynonymous mutation analysis, and should be applicable in analyzing the structural consequences of mutations in other contexts.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 29
- FWCI
- 0.80
- Field percentile
- top 30%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evolution of drug resistance drives progressive destabilizations in functionally conserved molecular dynamics of the flap region of the HIV-1 protease
Madhusudan Rajendran, Maureen C. Ferran, … Miranda L. Lynch·bioRxiv·Nov 22, 2022
- Structural Adaptation of Darunavir Analogs Against Primary Resistance Mutations in HIV-1 Protease
G.J. Lockbaum, Florian Leidner, … Celia A. Schiffer·ACS Infectious DiseasesPeer-reviewed·Dec 13, 2018
- Inference of epistatic effects leading to entrenchment and drug resistance in HIV-1 protease
William F. Flynn, Allan Haldane, … Ronald M. Levy·Molecular Biology and EvolutionPeer-reviewed·Feb 21, 2017
- Forecasting drug resistant HIV protease evolution
Manu Aggarwal, Vipul Periwal·PLoS Computational BiologyPeer-reviewed·Jan 27, 2026
- Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease
T.-h. Zhang, L. Dai, … R. Sun·bioRxiv·Oct 31, 2019
- Selection of HIV-1 for Resistance to Fifth Generation Protease Inhibitors Reveals Two Independent Pathways to High-Level Resistance
E. Spielvogel, S.-K. Lee, … R. Swanstrom·bioRxiv·Jun 23, 2022